Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases

Clinical Cancer Research

Volumn 10, Issue 13, 2004, Pages 4398-4405

  Koutsilieris, Michael ^a   Mitsiades, Constantine S ^a,b   Bogdanos, John ^a,c   Dimopoulos, Theodoros ^d   Karamanolakis, Dimitrios ^a,c   Milathianakis, Constantine ^a,c   Tsintavis, Athanassios ^c  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b HARVARD MEDICAL SCHOOL   (United States)

^c METAXA CANCER HOSPITAL   (Greece)

^d PANAGIA GENERAL HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE; ANTACID AGENT; ANTIANDROGEN; BICALUTAMIDE; CORTICOSTEROID; DEXAMETHASONE; ESTRAMUSTINE PHOSPHATE; ETOPOSIDE; FLUTAMIDE; GLUCOSE; GONADORELIN DERIVATIVE; MITOXANTRONE; OCTREOTIDE; PANCREAS ENZYME; PRASTERONE SULFATE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; RHENIUM; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR 2; STRONTIUM; TECHNETIUM 99M; TESTOSTERONE; TUMOR MARKER;

ABDOMINAL CRAMP; AGED; ARTICLE; BONE METASTASIS; BONE PAIN; BONE SCINTISCANNING; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; CUSHINGOID SYNDROME; DELIRIUM; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; LOW DRUG DOSE; MALE; MUSCLE WEAKNESS; ORCHIECTOMY; PAIN ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANDROGENS; ANTINEOPLASTIC AGENTS, HORMONAL; BONE NEOPLASMS; DEXAMETHASONE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GONADOTROPIN-RELEASING HORMONE; HORMONES; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIONUCLIDE IMAGING; SOMATOSTATIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 3042851917     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0077     Document Type: Article

References (37)

1. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer (Phila) 1993;71:1098-109.
2. Koutsilieris M, Tolis G. Long-term follow-up of patients with advanced prostatic carcinoma treated with either buserelin (HOE 766) or orchiectomy: classification of variables associated with disease outcome. Prostate 1985;7:31-9.
3. Koutsilieris M, Faure N, Tolis G, Laroche B, Robert G, Ackman CF. Objective response and disease outcome in 59 patients with stage D2 prostatic cancer treated with either Buserelin or orchiectomy. Disease aggressivity and its association with response and outcome. Urology 1986;27:221-8.
4. Koutsilieris M, Ackman CF. Complete response of lung metastases caused by prostatic cancer after chronic administration of a gonadotropin-releasing hormone analog, buserelin (HOE 766). Prostate 1987;10:19-24.
5. Koutsilieris M, Laroche B, Thabet M, Fradet Y. The assessment of disease aggressivity in stage D2 prostate cancer patients (review). Anticancer Res 1990;10:333-6.
6. Behrakis P, Koutsilieris M. Pulmonary metastases in metastatic prostate cancer: host tissue-tumor cell interactions and response to hormone therapy. Anticancer Res 1997;17:1517-8.
7. Mitsiades CS, Koutsilieris M. Molecular biology and cellular physiology of refractoriness to androgen ablation therapy in advanced prostate cancer. Expert Opin Investig Drugs 2001;10:1099-115.
8. Reyes-Moreno C, Sourla A, Choki I, Doillon C, Koutsilieris M. Osteoblast-derived survival factors protect PC-3 human prostate cancer cells from adriamycin apoptosis. Urology 1998;52:341-7.
9. Le Roith D, Bondy C, Yakar S, Liu JL, Butler A. The somatomedin hypothesis: 2001. Endocr Rev 2001;22:53-74.
10. Reyes-Moreno C, Frenette G, Boulanger J, Lavergne E, Govindan MV, Koutsilieris M. Mediation of glucocorticoid receptor function by transforming growth factor beta I expression in human PC-3 prostate cancer cells. Prostate 1995;26:260-9.
11. Boulanger J, Reyes-Moreno C, Koutsilieris M. Mediation of glucocorticoid receptor function by the activation of latent transforming growth factor beta 1 in MG-63 human osteosarcoma cells. Int J Cancer 1995;61:692-7.
12. Koutsilieris M, Tzanela M, Dimopoulos T. Novel concept of anti-survival factor (ASF) therapy produces an objective clinical response in four patients with hormone-refractory prostate cancer: case report. Prostate 1999;38:313-6.
13. Koutsilieris M, Mitsiades C, Dimopoulos T, Ioannidis A, Ntounis A, Lambou T. A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients. J Clin Endocrinol Metab 2001;86:5729-36.
14. 41st World Medical Assembly. Declaration of Helsinki: recommendations regarding physicians in biomedical research involving human subjects. J Am Med Assoc 1997;277:925-6.
15. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17:3461-7.
16. Halleen JM, Alatalo SL, Suominen H, Cheng S, Janckila AJ, Vaananen HK. Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res 2000;15:1337-45.
17. Davies PH, Stewart SE, Lancranjan L, Sheppard MC, Stewart PM. Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly. Clin Endocrinol (Oxf) 1998;48:311-6.
18. Spieth ME, Lin YG, Nguyen TT. Diagnosing and treating small-cell carcinomas of prostatic origin. Clin Nucl Med 2002;27:11-7.
19. Koutsilieris M. Osteoblastic metastasis in advanced prostate cancer. Anticancer Res 1993;13:443-9.
20. Soloway MS, Hardeman SW, Hickey D, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer (Phila) 1988;61:195-202.
21. Koutsilieris M, Polychronakos C. Proteinolytic activity against IGF-binding proteins involved in the paracrine interactions between prostate adenocarcinoma cells and osteoblasts. Anticancer Res 1992;12:905-10.
22. Koutsilieris M, Frenette G, Lazure C, Lehoux JG, Govindan MV, Polychronakos C. Urokinase-type plasminogen activator: a paracrine factor regulating the bioavailability of IGFs in PA-III cell-induced osteoblastic metastases. Anticancer Res 1993;13:481-6.
23. Mitsiades CS, Mitsiades N, McMullan CJ, et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies and solid tumors. Cancer Cell 2004;5:221-30.
24. Koutsilieris M, Rabbani SA, Goltzman D. Selective osteoblast mitogens can be extracted from prostatic tissue. Prostate 1986;9:109-15.
25. Koutsilieris M, Rabbani SA, Goltzman D. Effects of human prostatic mitogens on rat bone cells and fibroblasts. J Endocrinol 1987;115:447-54.
26. Koutsilieris M, Rabbani SA, Bennett HP, Goltzman D. Characteristics of prostate-derived growth factors for cells of the osteoblast phenotype. J Clin Investig 1987;80:941-6.
27. Polychronakos C, Janthly U, Lehoux JG, Koutsilieris M. Mitogenic effects of insulin and insulin-like growth factors on PA-III rat prostate adenocarcinoma cells: characterization of the receptors involved. Prostate 1991;19:313-21.
28. Koutsilieris M, Grondin F, Lehoux JG. The expression of mRNA for glucocorticoid receptor gene and functional glucocorticoid receptors detected in PA-III rat prostate adenocarcinoma cells. Anticancer Res 1992;12:899-904.
29. Koutsilieris M, Sourla A, Pelletier G, Doillon CJ. Three-dimensional type I collagen gel system for the study of osteoblastic metastases produced by metastatic prostate cancer. J Bone Miner Res 1994;9:1823-32.
30. Delany AM, Durant D, Canalis E. Glucocorticoid suppression of IGF I transcription in osteoblasts. Mol Endocrinol 2001;15:1781-9.
31. Reyes-Moreno C, Koutsilieris M. Glucocorticoid receptor function possibly modulates cell-cell interactions in osteoblastic metastases on rat skeleton. Clin Exp Metastasis 1997;15:205-17.
32. Koutsilieris M, Reyes-Moreno C, Sourla A, Dimitriadou V, Choki I. Growth factors mediate glucocorticoid receptor function and dexamethasone-induced regression of osteoblastic lesions in hormone refractory prostate cancer. Anticancer Res 1997;17:1461-5.
33. Small EJ, Harris KA. Secondary hormonal manipulation of prostate cancer. Semin Urol Oncol 2002;20:24-30.
34. Figg WD, Thibault A, Cooper MR, et al. A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone-refractory prostate cancer. Cancer (Phila) 1995;75:2159-64.
35. Maulard C, Richaud P, Droz JP, Jessueld D, Dufour-Esquerre F, Housset M. Phase I-II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer. Cancer Chemother Pharmacol 1995;36:259-62.
36. Schally AV, Nagy A. New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin. Life Sci 2003;72:2305-20.
37. Nishimura K, Nonomura N, Satoh E, et al. Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. J Natl Cancer Inst (Bethesda) 2001;93:1739-46.